JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

The long noncoding RNA MIR4435-2HG enhances the migration, promotion, and glycolysis of nonsmall cell lung cancer cells by targeting the miR-371a-5p/SOX2/PI3K/Akt axis

  • 0Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Sage Open Medicine +

|

November 11, 2024

|

November 11, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Long noncoding RNA MIR4435-2HG promotes nonsmall cell lung cancer progression by enhancing cell proliferation, migration, and glycolysis. It acts via the miR-371a-5p/SOX2 axis, offering a potential therapeutic target for this deadly cancer.

Area Of Science

  • Oncology
  • Molecular Biology
  • RNA Biology

Background

  • Nonsmall cell lung cancer (NSCLC) is a major cause of cancer mortality globally.
  • The long noncoding RNA MIR4435-2HG is implicated in the carcinogenicity of various cancers.
  • Understanding MIR4435-2HG's role in NSCLC is crucial for developing targeted therapies.

Purpose Of The Study

  • To investigate the function of MIR4435-2HG in NSCLC.
  • To elucidate the regulatory mechanism of MIR4435-2HG in NSCLC progression.
  • To explore the potential of MIR4435-2HG as a therapeutic target.

Main Methods

  • Quantitative real-time PCR to measure MIR4435-2HG and SOX2 expression.
  • In vitro gain- and loss-of-function assays to assess cell behavior (proliferation, apoptosis, migration, invasion, glycolysis).
  • In vivo nude mouse tumor model and dual-luciferase reporter assays to analyze molecular interactions.

Main Results

  • MIR4435-2HG and SOX2 were upregulated in NSCLC cells.
  • MIR4435-2HG overexpression increased proliferation, migration, invasion, and glycolysis while decreasing apoptosis.
  • MIR4435-2HG acts as a competing endogenous RNA, targeting miR-371a-5p and upregulating SOX2, thereby promoting NSCLC progression.

Conclusions

  • MIR4435-2HG drives NSCLC malignant behaviors and glycolysis through the miR-371a-5p/SOX2 pathway.
  • Downregulating MIR4435-2HG exhibits antitumor effects.
  • Targeting the MIR4435-2HG/miR-371a-5p/SOX2 axis represents a promising therapeutic strategy for NSCLC.

Keywords: